跳至主要内容
临床试验/NCT02180737
NCT02180737已完成4 期

Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures

National Cancer Institute, Egypt1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
verbal analogue scale

研究概览

简要总结

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age from 18-65 years old
  • ASA physical status of I-II
  • Expected procedure lasting at least 30 minutes

排除标准

  • Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block.
  • An alpha2-agonist or antagonist within 14 days before the scheduled procedure.
  • patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration.
  • Patients who are allergic to Dexmedetomidine or alpha 2-agonists.

研究组 & 干预措施

Dexmeditomedine

Experimental

Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.

干预措施: Dexmeditomedine (Drug)

结局指标

主要结局

verbal analogue scale

时间窗: 1 hour

assessment of pain using VAS score

Degree of sedation

时间窗: 1 hour

It will be measured and recorded by using the Ramsay sedation score.

次要结局

  • patient satisfaction(24 hours)

研究者

发起方
National Cancer Institute, Egypt
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ghada M N Bashandy

Dr

National Cancer Institute, Egypt

研究点 (1)

Loading locations...

相似试验